BridgeMD
Treatment of opioid dependency in patients with chronic pain: a comparative study between suboxone and methadone.
EU CTIS ID: 2024-513924-41-01
What this study is testing
To compare the effectivity of suboxone (buprenorphine/naloxone) and methadone on reducing self-reported opioid misuse.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18 or over.
- Meet ICD-11 criteria for chronic non-cancer pain.
- Using a prescribed opioid with a morphine equivalent dose of over 60 mg per day for ≥3 months.
- Have an opioid use disorder according to the DSM-5.
- Wish to be treated for opioid use disorder.
- Willing to comply to study procedures.
You likely can't join if
- Pregnant, lactating, or planning to become pregnant during the study period.
- Have already used buprenorphine or methadone in the last 4 weeks as a maintenance therapy.
- Escalated use of another substance that prevents safe participation in the study.
- Have acute psychiatric comorbidity.
- Severe respiratory insufficiency or depression, such as severe chronic obstructive pulmonary disease GOLD 3 or 4.
- Serious medical disease, such as severe liver dysfunction (Child-Pugh B or C), severe renal dysfunction (eGFR (MDRD) ≤29), heart failure, current brain trauma).
See the full eligibility criteria
- Age 18 or over.
- Meet ICD-11 criteria for chronic non-cancer pain.
- Using a prescribed opioid with a morphine equivalent dose of over 60 mg per day for ≥3 months.
- Have an opioid use disorder according to the DSM-5.
- Wish to be treated for opioid use disorder.
- Willing to comply to study procedures.
- Be able to give informed consent.
- Pregnant, lactating, or planning to become pregnant during the study period.
- Have already used buprenorphine or methadone in the last 4 weeks as a maintenance therapy.
- Escalated use of another substance that prevents safe participation in the study.
- Have acute psychiatric comorbidity.
- Severe respiratory insufficiency or depression, such as severe chronic obstructive pulmonary disease GOLD 3 or 4.
- Serious medical disease, such as severe liver dysfunction (Child-Pugh B or C), severe renal dysfunction (eGFR (MDRD) ≤29), heart failure, current brain trauma).
- A Q-T interval of ≥450 ms on an electrocardiograph (ECG).
- Hypersensitivity or allergy for buprenorphine, naloxone, methadone or any other substance in the preparations of these medications.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.